ARTICLE | Clinical News
Trisenox arsenic trioxide (ATO): Began Phase II testing
February 5, 2001 8:00 AM UTC
Cell Therapeutics Inc. (CTIC), Seattle, Wash. Product: Trisenox arsenic trioxide (ATO) Business: Cancer Therapeutic category: Apoptosis, Cell proliferation Target: DNA, and PML- RAR alpha fusion prot...